Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. - Wikidata - awgldk - TriplyDB

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

http://www.wikidata.org/entity/Q40244899

about

Nomograms for predicting recurrence and survival of invasive pathological stage IA non-small cell lung cancer treated by video assisted thoracoscopic surgery lobectomy.Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration.Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Appropriateness of imaging for lung cancer staging in a national cohort Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy Pharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China.Managing the genomic revolution in cancer diagnostics.EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.Editorial on: multidisciplinary therapy of marginally operable stage IIIA non-small cell lung cancer.Spotlight on landmark oncology trials: the latest evidence and novel trial designs.Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care.Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges.Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report.Molecular Targets in Non-Small Cell Lung Cancer.Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again?Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.Semi-rigid single hook localization the best method for localizing ground glass opacities during video-assisted thoracoscopic surgery: re-aerated swine lung experimental and primary clinical results.Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung.Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer.Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.Multicenter study of diagnostic procedures, genetic aberration analysis, and first-line treatment of lung cancer in Jiangsu Province, China.Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.Microarray profile of circular RNAs identifies hsa_circ_0014130 as a new circular RNA biomarker in non-small cell lung cancer.Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.YAP regulates PD-L1 expression in human NSCLC cells.

P2860

Q33639243-EAB65A6A-7843-463A-A24D-9398151E44BA Q33743535-1770CBE4-035B-4F3F-9431-290F45BA668D Q33763622-53B72816-0D46-49FC-82A1-C263341C39B4 Q33778668-758CE941-8213-4357-91EB-AE56C54804DE Q34332850-04A9F558-47A1-4022-BD67-25C6C5CF1DDE Q37150582-588C6959-0BC8-48C1-9C2D-539A546B149D Q38369354-78D260D1-06F2-4A19-AAE3-FE27586A0253 Q38598893-544E4288-2886-41B3-9911-F06D57C2FFD1 Q38603487-B47EA856-E4F0-450A-A2C2-B5069156AF7B Q38714606-CFCE31AC-2A16-4591-9B4A-6B0C961E5920 Q41107790-AD22E00A-4C80-4FF8-9ECC-D5BAE74B7C7A Q41233416-F10BE632-B0D6-4968-929A-17F7AD44A0E4 Q41536996-86BAC317-8B92-40F5-8D5A-8C681FEB1BFF Q41670014-6C6E42F1-16A6-4AC9-A083-10A2EFAFFAC9 Q42342006-9931E8F3-1122-4B2D-97C3-C3A2313B0DAB Q42343618-580674D1-6FAE-456B-894C-F5AE035999B3 Q42673256-BE0EEFDA-277D-408C-B700-E2A99145FDE3 Q43973311-788879F6-8C0B-46DE-B85B-0620D370A9A7 Q43994049-2D4036CE-9279-4167-90B4-C9C559F7DF53 Q45891469-B2F7D437-70C5-4A4E-A401-8DE9F47C88AB Q47108604-9CA01210-05B9-4275-8020-E2DAE20454E0 Q47125750-2C3B23DA-1DB6-461E-B3A2-678F409F4C98 Q47141828-DD4F9917-21CB-4183-945B-42BC02CF342B Q47142109-062B7C62-6497-42F3-BB36-1E589806D053 Q47148981-A55C679F-6970-40C4-84ED-76E83373D154 Q47155582-7D2A1FBE-ED3C-4B0B-87DC-EA2D56FF9405 Q47173885-65FC64DA-506A-46E2-A076-4908E20FD098 Q47274741-173CCB9B-D356-42CD-8ADC-436F4134D4B4 Q47418565-18A4DB2A-9B68-4FB2-B337-1AADD32EE73F Q47420701-69948925-0753-47A5-A59C-97198FDC9A98 Q47574237-FA908C88-1776-4ABC-A4D1-35C599F9CB04 Q47578326-C0581D2A-4FF9-48C6-92EF-2B10A09BBAE0 Q47654942-6AF6B1B3-4E6C-4CDD-A12B-4ABA80D428E8 Q48126555-DC4DC669-2350-4451-B6AB-8EAB9D80E113 Q48369218-7F99621C-9779-45E3-86E5-E896EC3F088D Q48535444-11F59702-F20A-499D-97AE-FB329296D427 Q49388126-A4FBC121-6612-4676-A8DF-CACF88F657BE Q49404537-29903E25-E4EA-4A95-AC5D-23B1D0291E88 Q49409530-BB271484-6CCB-41D9-9840-F4EEE50FF008 Q49569691-FEE35D59-C531-4EE8-A039-6B41FEE38070

P2860

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

http://www.wikidata.org/entity/Q40244899

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.

@en

type

label

Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.

@en

prefLabel

Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.

@en

P1433

Q40244899-9E93183A-8DA9-4FE3-A453-30C955AF8BBD

P1476

Q40244899-B53F2CD4-9AF5-483B-A115-00955A208565

P2093

Q40244899-0077C972-79C2-4725-9969-6F3C3CF803A6

Q40244899-02BBD7C6-7E23-4F2F-ACF4-938949E58C37

Q40244899-10748A48-406D-4A7A-80DD-04BFCA6EB427

Q40244899-19634C6B-637B-455B-8FAB-A999EFB45608

Q40244899-21A27249-5D63-4785-B4A5-179DF9E0160E

Q40244899-285F5939-11E8-4C2F-98C8-CFB5CA0CFA8E

Q40244899-2E925E4E-8FA4-4575-B22D-48C1144F816B

Q40244899-31081CEC-E591-4620-85A1-9879C879EE01

Q40244899-39968D2C-721E-4481-B313-B625A5D579D1

Q40244899-41A84610-6E56-42E4-955D-C49890CCAA3E

P304

Q40244899-9361F07E-7B25-42C6-ABB6-67E874C74965

P31

Q40244899-C9EA9724-C68C-450C-8A64-ECDD70E5D711

P356

Q40244899-0C98AE90-3FF3-49BA-8A64-7EAD19E8C839

P433

Q40244899-96BD2C1D-BA86-4349-A3C9-1AAB58DD8A94

P478

Q40244899-7625C31E-4DE5-4B8D-969E-ECD8157DB179

P50

Q40244899-2B30204D-20CB-4FB1-83D6-480785CA248F

P577

Q40244899-351F8079-A3EA-49B3-B59A-B9BF932E9081

P698

Q40244899-B575524F-D95A-436C-A45E-8658D6DA6D97

P356

JNCCN.2017.0050

P1433

Journal of the National Comprehensive Cancer Network

P1476

Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.

@en

P2093

Billy W Loo

http://www.w3.org/2001/XMLSchema#string

Dara L Aisner

http://www.w3.org/2001/XMLSchema#string

David S Ettinger

http://www.w3.org/2001/XMLSchema#string

Douglas E Wood

http://www.w3.org/2001/XMLSchema#string

Gregory A Otterson

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

James Stevenson

http://www.w3.org/2001/XMLSchema#string

Jessica Bauman

http://www.w3.org/2001/XMLSchema#string

Jules Lin

http://www.w3.org/2001/XMLSchema#string

Karen Reckamp

http://www.w3.org/2001/XMLSchema#string

P304

504-535

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JNCCN.2017.0050

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28404761

http://www.w3.org/2001/XMLSchema#string